This report discusses the chemistry, efficacy, toxicity, specificity, and mechanism of action of antibody drug conjugates (ADCs) in cancer therapy. It also covers the advantages and disadvantages of ADCs. ADCs are monoclonal antibodies that bind to biologically active drugs with the help of linkers by labile bonds. The chemistries of conjugation and linker play an important part in constructing ADCs. The hydrophobic linker helps to aggregate the ADCs. The ADCs also have toxicity such as hepatic, neurologic, and ophthalmic events that can occur due to the premature release of payloads in the bloodstream. The ADC therapy has efficacy to eliminate the infected cells directly by arresting the G2/M phase. This therapy can be useful in various types of cancer such as ovarian cancer, pancreatic cancer, breast cancer, prostate cancer, renal carcinoma, and colorectal cancer.
![[object Object]](/_next/image/?url=%2F_next%2Fstatic%2Fmedia%2Flogo.6d15ce61.png&w=640&q=75){kind=small}
![[object Object]](/_next/static/media/star-bottom.7253800d.svg)
